Interaction between CYP2D6 inhibitor antidepressants and codeine: is this relevant?
Lucie Cazet1, Samuel Bulteau2,3, Adrien Evin4
1a CPAM Pays-de-la-Loire , Echelon Régional du Service Médical , Nantes , France.
Expert Opinion on Drug Metabolism & Toxicology
|July 3, 2018
Summary
Concurrent use of antidepressants and codeine can lead to inadequate pain relief due to cytochrome P450 2D6 enzyme inhibition. Healthcare professionals must avoid this drug combination to ensure effective pain management and depression treatment.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Drug Interactions
Background:
- Co-occurring pain and depression negatively impact patient prognosis.
- Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are common depression treatments that inhibit CYP2D6.
- Codeine, a pain reliever, requires CYP2D6 metabolism to morphine for analgesia.
Purpose of the Study:
- To review the clinical effects of co-prescribing codeine with CYP2D6-inhibiting antidepressants.
- To quantify the prevalence of this drug combination in clinical practice.
Main Methods:
- Systematic literature review on the clinical impact of the drug association.
- Retrospective observational cohort study in the French Pays de la Loire area (January 2015 - June 2015).
Main Results:
- Literature indicates that antidepressants with moderate-to-strong CYP2D6 inhibition should be avoided with codeine.
- 0.44% of 12,296 patients received concomitant codeine and a CYP2D6 inhibitor.
- Drug switching strategies depend on specific pain and depression subtypes.
Conclusions:
- Concomitant prescription of codeine and CYP2D6 inhibitors leads to inadequate analgesia and requires clinical attention.
- Enhanced communication and education for healthcare professionals are crucial to prevent these interactions.
- Future research is exploring novel therapeutics targeting both pain and depression.
Related Concept Videos
01:52Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
01:25Antidepressant Drugs: Overview
1.6K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.6K
01:23Antidepressant Drugs: MAOIs and Other Agents
945
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
945
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.6K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.6K
01:23Dipeptidyl Peptidase 4 Inhibitors
686
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
686
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
222
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
222